Dashboard
1
Flat results in Mar 25
- INTEREST(HY) At CNY 140.42 MM has Grown at 32.97%
- ROCE(HY) Lowest at 17.85%
2
With ROE of 16.83%, it has a expensive valuation with a 4.38 Price to Book Value
3
Majority shareholders : Non Institution
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 94,929 Million (Large Cap)
26.00
NA
1.57%
-0.14
16.83%
4.38
Revenue and Profits:
Net Sales:
5,467 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,053 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.71%
0%
-18.71%
6 Months
-24.16%
0%
-24.16%
1 Year
-4.16%
0%
-4.16%
2 Years
-42.87%
0%
-42.87%
3 Years
-48.56%
0%
-48.56%
4 Years
-71.56%
0%
-71.56%
5 Years
-40.8%
0%
-40.8%
Aier Eye Hospital Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.47%
EBIT Growth (5y)
19.94%
EBIT to Interest (avg)
25.06
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
0.92
Tax Ratio
18.05%
Dividend Payout Ratio
41.71%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
36.77%
ROE (avg)
21.32%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
4.38
EV to EBIT
20.37
EV to EBITDA
13.78
EV to Capital Employed
4.93
EV to Sales
4.19
PEG Ratio
NA
Dividend Yield
1.57%
ROCE (Latest)
24.18%
ROE (Latest)
16.83%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Jun 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
5,467.20
5,335.40
2.47%
Operating Profit (PBDIT) excl Other Income
1,826.50
1,730.60
5.54%
Interest
67.40
64.00
5.31%
Exceptional Items
30.60
173.10
-82.32%
Consolidate Net Profit
1,053.20
1,236.30
-14.81%
Operating Profit Margin (Excl OI)
228.30%
235.60%
-0.73%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 2.47% vs 2.27% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -14.81% vs 19.53% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
20,916.20
20,318.50
2.94%
Operating Profit (PBDIT) excl Other Income
6,403.10
6,936.90
-7.70%
Interest
300.00
245.20
22.35%
Exceptional Items
146.60
-463.00
131.66%
Consolidate Net Profit
3,736.10
3,656.00
2.19%
Operating Profit Margin (Excl OI)
213.00%
259.40%
-4.64%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 2.94% vs 26.47% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 2.19% vs 35.96% in Dec 2023
About Aier Eye Hospital Group Co., Ltd. 
Aier Eye Hospital Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






